SI
REGN icon

Stephens Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

Stephens Inc’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$686K Buy
887
+357
+67% +$273K 0.01% 759
2025
Q4 		$409K Sell
530
-11
-2% -$7.47K 0.01% 915
2025
Q3 		$304K Sell
541
-207
-28% -$117K ﹤0.01% 1042
2025
Q2 		$393K Sell
748
-145
-16% -$80.9K 0.01% 917
2025
Q1 		$566K Sell
893
-55
-6% -$37.8K 0.01% 770
2024
Q4 		$675K Sell
948
-6
-0.6% -$5.04K 0.01% 721
2024
Q3 		$1M Sell
954
-1
-0.1% -$1.11K 0.01% 605
2024
Q2 		$1M Buy
955
+42
+5% +$40.7K 0.02% 588
2024
Q1 		$879K Buy
913
+192
+27% +$183K 0.01% 619
2023
Q4 		$633K Buy
721
+84
+13% +$69.2K 0.01% 665
2023
Q3 		$524K Sell
637
-5
-0.8% -$3.93K 0.01% 711
2023
Q2 		$461K Sell
642
-5
-0.8% -$3.85K 0.01% 763
2023
Q1 		$532K Sell
647
-72
-10% -$54.3K 0.01% 699
2022
Q4 		$519K Hold
719
– – 0.01% 690
2022
Q3 		$495K Sell
719
-10
-1% -$6.29K 0.01% 711
2022
Q2 		$431K Sell
729
-3
-0.4% -$1.95K 0.01% 776
2022
Q1 		$511K Hold
732
– – 0.01% 798
2021
Q4 		$462K Sell
732
-5
-0.7% -$3.07K 0.01% 874
2021
Q3 		$446K Sell
737
-7
-0.9% -$4.35K 0.01% 916
2021
Q2 		$416K Sell
744
-100
-12% -$50.7K 0.01% 936
2021
Q1 		$399K Sell
844
-13,401
-94% -$6.52M 0.01% 913
2020
Q4 		$6.88M Buy
14,245
+978
+7% +$528K 0.12% 172
2020
Q3 		$7.43M Buy
13,267
+249
+2% +$151K 0.15% 143
2020
Q2 		$8.12M Sell
13,018
-145
-1% -$82.3K 0.17% 131
2020
Q1 		$6.43M Buy
13,163
+1,670
+15% +$689K 0.17% 136
2019
Q4 		$4.32M Buy
11,493
+1,866
+19% +$628K 0.09% 247
2019
Q3 		$2.67M Buy
9,627
+492
+5% +$146K 0.06% 333
2019
Q2 		$2.86M Sell
9,135
-149
-2% -$49.6K 0.06% 324
2019
Q1 		$3.81M Buy
9,284
+8
+0.1% +$3.29K 0.09% 261
2018
Q4 		$3.46M Buy
9,276
+249
+3% +$91.1K 0.1% 247
2018
Q3 		$3.65M Buy
+9,027
New +$3.44M 0.09% 273
2017
Q3 		– Sell
-8,097
Closed -$3.98M – 844
2017
Q2 		$3.98M Buy
8,097
+1,863
+30% +$815K 0.14% 170
2017
Q1 		$2.42M Buy
6,234
+1,609
+35% +$596K 0.09% 247
2016
Q4 		$1.7M Buy
4,625
+1,653
+56% +$629K 0.07% 294
2016
Q3 		$1.2M Buy
2,972
+442
+17% +$177K 0.05% 339
2016
Q2 		$884K Sell
2,530
-10
-0.4% -$3.85K 0.04% 378
2016
Q1 		$916K Buy
2,540
+52
+2% +$21.4K 0.04% 346
2015
Q4 		$1.35M Buy
2,488
+190
+8% +$103K 0.07% 287
2015
Q3 		$1.07M Buy
2,298
+23
+1% +$12.4K 0.06% 321
2015
Q2 		$1.16M Buy
2,275
+78
+4% +$38.1K 0.05% 340
2015
Q1 		$992K Buy
2,197
+135
+7% +$57.2K 0.05% 363
2014
Q4 		$846K Sell
2,062
-134
-6% -$52.7K 0.04% 379
2014
Q3 		$792K Buy
2,196
+781
+55% +$262K 0.04% 380
2014
Q2 		$400K Buy
1,415
+98
+7% +$29K 0.02% 551
2014
Q1 		$395K Buy
1,317
+268
+26% +$82.6K 0.02% 520
2013
Q4 		$289K Buy
1,049
+108
+11% +$31.1K 0.01% 659
2013
Q3 		$294K Buy
+941
New +$248K 0.02% 602

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Stephens Inc's REGN Position: Q1 2026 in Review

Stephens Inc increased its Regeneron Pharmaceuticals (REGN) stake by 67% in Q1 2026, buying an estimated $273K and bringing the position to 887 shares worth $686K. The position accounts for 0.01% of the portfolio, ranked #759.

Stephens Inc first reported a position in REGN in Q3 2013 and has held it in 47 quarters since. The position peaked at $8.12M in Q2 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Stephens Inc held 887 shares of Regeneron Pharmaceuticals worth $686K as of Q1 2026.
  • Stephens Inc bought 357 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $273K.
  • Regeneron Pharmaceuticals made up 0.01% of Stephens Inc's portfolio in Q1 2026, its #759 holding.
  • Stephens Inc first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 47 quarters since.
  • Stephens Inc's Regeneron Pharmaceuticals position peaked at $8.12M in Q2 2020.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Stephens Inc's 13F filing for Q1 2026, filed 28 Apr 2026.